このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

OPN-375 思春期の両側鼻ポリープ患者における有効性と安全性

2026年9月15日 更新者:Optinose US Inc.

OPN-375 186 μg の有効性と安全性を評価する 16 週間の無作為化二重盲検プラセボ対照並行群間多施設研究 両側鼻ポリープのある青年を対象に 1 日 2 回、その後 12 週間の非盲検治療段階を実施

This is a 16-Week Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of OPN-375 186 μg Twice a Day (BID) in Adolescents with Bilateral Nasal Polyps followed by a 12-Week Open-Label Treatment Phase. The total planned number of subjects is approximately 72 adolescents (12-17 years of age) who will be randomly assigned to receive 1 of 2 study treatments using a 2:1 ratio (OPN-375 186 μg: Placebo). For the PK sub-study, up to 14 subjects will be enrolled to obtain 10 completers.

調査の概要

状態

完了

介入・治療

詳細な説明

The primary objective of this study is to evaluate the efficacy of intranasal administration of OPN-375 186 μg Twice a Day (BID) versus placebo in adolescents with bilateral nasal polyposis and nasal congestion by analyzing the reduction of nasal congestion/obstruction symptoms at the end of Week 4 measured by the 7-day average instantaneous morning diary symptom scores and the reduction in total polyp grade at Week 16 as determined by a nasal polyp grading scale score measured using a 0 to 6 point severity grading scale.

研究の種類

介入

入学 (実際)

40

段階

  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Arizona
      • Gilbert、Arizona、アメリカ、85234
        • San Tan Allergy & Asthma
    • California
      • Bakersfield、California、アメリカ、93301
        • Kern Research
      • Fresno、California、アメリカ、93720
        • Central California Clinical Research
      • Los Angeles、California、アメリカ、90027
        • Children's Hospital of Los Angeles
      • Los Angeles、California、アメリカ、90006
        • Sensa Health
      • Orange、California、アメリカ、92868
        • Children's Hospital of Orange County
      • Redwood City、California、アメリカ、94063
        • Allergy and Asthma Consultants
      • Roseville、California、アメリカ、95661
        • Sacramento ENT
      • San Diego、California、アメリカ、92123
        • Rady Children's Hospital San Diego
    • Colorado
      • Aurora、Colorado、アメリカ、80045
        • Children's Hospital Colorado
    • Georgia
      • Atlanta、Georgia、アメリカ、30322
        • Children's Healthcare of Atlanta
    • Illinois
      • Chicago、Illinois、アメリカ、60657
        • Chicago ENT
    • Kentucky
      • Louisville、Kentucky、アメリカ、40205
        • Kentuckiana ENT
    • New York
      • Rochester、New York、アメリカ、14642
        • University of Rochester
    • North Carolina
      • Charlotte、North Carolina、アメリカ、28204
        • Allergy Asthma & Immunology Research Institute
    • Oklahoma
      • Oklahoma City、Oklahoma、アメリカ、73120
        • Allergy, Asthma & Clinical Research Center
      • Tulsa、Oklahoma、アメリカ、74136
        • Vital Prospects Clinical Research Institute, P.C.
    • South Carolina
      • Orangeburg、South Carolina、アメリカ、29118
        • Carolina ENT
    • Texas
      • San Antonio、Texas、アメリカ、78229
        • STAAMP Research
    • Utah
      • Salt Lake City、Utah、アメリカ、84132
        • University of Utah
    • Virginia
      • Norfolk、Virginia、アメリカ、23507
        • Eastern Virginia Medical School - Otolaryngology
    • Washington
      • Spokane Valley、Washington、アメリカ、99216
        • Spokane ENT
      • Buenos Aires、アルゼンチン、C1411ABE
        • Fundacion CIDEA
      • Buenos Aires、アルゼンチン、C1425BEN
        • InAER - Investigaciones en Alergia y Enfermedades Respiratorias
      • Buenos Aires、アルゼンチン、C1180AAX
        • Sanatorio Guemes
      • Corrientes、アルゼンチン、W3400AVV
        • Instituto de Asma Alergia y Enfermedades Respiratoria (IAAER)
      • Mendoza、アルゼンチン、M5500CCG
        • Centro Medico INSARES
    • Córdoba Province
      • Río Cuarto、Córdoba Province、アルゼンチン、X5008AEV
        • Instituto Medico Rio Cuarto
    • Santa Fe Province
      • Rosario、Santa Fe Province、アルゼンチン、S2000DEJ
        • Instituto Medico de la Fundacion de Estudios Clinicos - Consultorios Integrados Rosario
      • Rosario、Santa Fe Province、アルゼンチン、S200DBS
        • Centro de Investigaciones Clinicas - Instituto de la Salud Rosario
    • Tucumán Province
      • San Miguel de Tucumán、Tucumán Province、アルゼンチン、T4000IHE
        • Clinica Mayo, UMCB

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

12年~17年 (子)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Male or female subjects aged 12 to 17 years, inclusive, at time of Visit 1 (Screening).

  2. Female subjects, if sexually active, must,

    1. be practicing an effective method of birth control (e.g., prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device, double-barrier method [e.g., condoms, diaphragm, or cervical cap with spermicidal foam, cream, or gel], or male partner sterilization) before entry and throughout the study, or
    2. be surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal ligation, or otherwise be incapable of pregnancy), or
    3. be abstinent.
  3. All female subjects not documented to be infertile (e.g., infertility due to congenital abnormality or surgical sterilization) must have a negative serum or urine beta-human chorionic gonadotropin (hCG) at Visit 1 (Screening) and a negative urine pregnancy test at the Visit 2 (Day 1/Randomization/Baseline).

  4. Must have bilateral nasal polyposis with a grade of 1 to 3 in each of the nasal cavities as determined by a nasal polyp grading scale score measured by nasoendoscopy at Visit 1 (Screening).

  5. Must report at least mild symptoms of nasal congestion/obstruction as demonstrated by an average morning nasal congestion/obstruction score of at least 1.0 over a 7 day period during the single-blind run-in period. (Subjects not meeting this inclusion criterion may be re-screened once after at least 4 weeks.)

  6. Subjects with comorbid asthma must be stable, defined as no exacerbations (e.g., no emergency room visits, hospitalization, or oral or parenteral steroid use) within the 3 months before Visit 1 (Screening). Subjects who received inhaled corticosteroids are required to be on no more than a moderate dosage regimen as defined by 2015 Global Initiative for Asthma Guidelines (GINA) for 1 month before Visit 1 (Screening) and to be expected to remain on it throughout the study (GINA 2015). Subjects receiving inhaled fluticasone alone or in combination may not participate in the PK sub-study.

  7. Must be able to cease treatment with intranasal medications including, but not limited to, intranasal oxymetazoline or any other decongestants, intranasal antihistamines, intranasal steroids, intranasal sodium cromolyn, nasal atropine, nasal ipratropium bromide, inhaled corticosteroids (except permitted doses listed above for asthma) at Visit 1 (Screening). [Note: intranasal antibiotics and saline are permissible]

  8. If taking oral antihistamines, must be on a stable regimen for at least 2 weeks prior to Visit 1 (Screening), and agree to not change the dose of these medications until after Visit 3 (Week 4) of the study.

  9. Subjects (with assistance from parent or legal guardian if needed) must demonstrate the ability to complete the daily diary during the run-in period to be eligible for randomization.

  10. Must demonstrate correct use of the demo EDS.

  11. Must be capable, in the opinion of the investigator, of providing assent and the appropriate parent(s) or guardian must provide an informed consent to participate in the study.

Exclusion Criteria:

  1. Pregnancy or lactation
  2. Has a history of cystic fibrosis
  3. Have used XHANCE (fluticasone propionate) nasal spray within the past 2 months
  4. Inability to achieve bilateral nasal airflow for any reason, including nasal septum deviation
  5. Inability to examine both nasal cavities for any reason, including severe nasal septum deviation
  6. Have known history of nasal septum erosion, ulceration or perforation, or evidence of such lesion on Visit 1 (Screening) nasal examination/nasoendoscopy
  7. Other significant nasal pathology or abnormal anatomy
  8. Has had any episode of epistaxis with frank bleeding in the 3 months before Visit 1 (Screening)
  9. History of more than 5 sinus or nasal surgeries for either nasal polyps or nasal/sinus inflammation (lifetime)
  10. Have had any surgery on the nasal septum
  11. History of sinus or nasal surgery within 6 months before Visit 1 (Screening)
  12. History of any surgical procedure that prevents the ability to accurately diagnose or grade polyps
  13. Current, ongoing rhinitis medicamentosa (rebound rhinitis)
  14. Have significant oral structural abnormalities (e.g., a cleft palate)
  15. History of Churg-Strauss syndrome or dyskinetic ciliary syndromes
  16. Purulent nasal infection (recent fever or symptoms of lethargy), acute sinusitis, or upper respiratory tract infection within 2 weeks before Visit 1 (Screening). Potential subjects presenting with one of these infections may be rescreened after 4 weeks.
  17. Have an allergy, hypersensitivity, or contraindication to corticosteroids or steroids
  18. Have a hypersensitivity to any excipients in the study drug
  19. Exposure to any glucocorticoid treatment with potential for systemic effects (e.g., oral or parenteral steroids, high dose topical steroids) within 1 month before Visit 1 (Screening); except as noted in inclusion criteria for subjects with comorbid asthma
  20. Have received mepolizumab (Nucala®), reslizumab (Cinquair®), dupilumab (Dupixent®), omalizumab (Xolair®), or benralizumab (Fasenra™) within 6 months of Visit 1
  21. Have nasal or oral candidiasis
  22. Have taken a potent CYP3A4-inhibitor within 14 days before Visit 1 (Screening)
  23. Any serious or unstable concurrent disease, psychiatric disorder, or any significant concomitant medical condition that, in the opinion of the investigator could confound the results of the study or could interfere with the subject's participation or compliance in the study, or pose a specific risk to the subject due to study participation
  24. History or current diagnosis of any form of glaucoma or ocular hypertension (i.e., >21 mm Hg)
  25. History of intraocular pressure elevation on any form of steroid therapy
  26. Current diagnosis of the presence (in either eye) of a cataract of Grade 1 or greater as defined on the Eye Examination Worksheet OR, less than a Grade 1 cataract with associated visual impairment
  27. A recent (within 1 year of Visit 1 [Screening]) history of drug or alcohol abuse or dependence
  28. Positive urine drug screen at screening visit for stimulants, opioids, or cocaine
  29. Have participated in an investigational drug clinical trial within 30 days of Visit 1 (Screening)
  30. Parents, guardian or caregivers of the subject who are employees of the investigator or study center, with direct involvement in the proposed study or other studies under the direction of that investigator or study center, as well as family members of the employees or the investigator.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:ダブル

武器と介入

参加者グループ / アーム
介入・治療
アクティブコンパレータ:OPN-375 186 μg BID

Double-Blind Treatment Phase: OPN-375 186 μg BID x 16 weeks

Open-Label Extension Phase: OPN-375 186 μg BID x 12 weeks

OPN-375, BID

プラセボコンパレーター:Placebo

Double-Blind Treatment Phase: Matching Placebo BID x 16 weeks

OPN-375, BID

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Change in nasal congestion/obstruction symptoms (mild, moderate, severe) at the end of Week 4
時間枠:4 Weeks

Change in nasal congestion/obstruction symptoms at the end of Week 4 measured by the 7-day average instantaneous morning (AM) diary symptom scores (ADS7-IA). The nasal symptom scale is what is used to score the nasal congestion/obstruction score, which is recorded in the diary. Nasal symptom scale is graded on a scale of 0=no symptom, 1=mild symptom, 2=moderate symptom, 3=severe symptom.

4 Weeks
Mean change from baseline at Week 16 in total polyp grade
時間枠:16 Weeks

Change in total polyp grade (sum of scores from both nasal cavities) at Week 16 as determined by a nasal polyp grading scale score measured using a 0 to 6 point severity grading scale, with 0 (no polyps) to 3 (severe polyps) points per nostril

16 Weeks

二次結果の測定

結果測定
メジャーの説明
時間枠
Change in bilateral polyp grade over time
時間枠:16 Weeks

nasal polyp grading scale score measured using a 0 to 6 point severity grading scale, with 0 (no polyps) to 3 (severe polyps) points per nostril

16 Weeks
Percentage of subjects with a ≥1 point improvement in polyp grade
時間枠:16 Weeks

nasal polyp grading scale score measured using a 0 to 6 point severity grading scale, with 0 (no polyps) to 3 (severe polyps) points per nostril

16 Weeks
Percentage of subject with a grade of 0 on at least one side of the nose
時間枠:16 Weeks

nasal polyp grading scale score measured using a 0 to 6 point severity grading scale, with 0 (no polyps) to 3 (severe polyps) points per nostril

16 Weeks
Change in diary symptom scores for the symptoms of nasal congestion/obstruction, measured as instantaneous and reflective scores for the morning and the afternoon (AM and PM scores)
時間枠:16 Weeks

The Nasal Symptom Scale is graded on a scale of 0 (no symptom) to 3 (Severe symptom)

16 Weeks
Change in diary symptom scores for the symptoms of rhinorrhea, measured as instantaneous and reflective scores for the morning and the afternoon (AM and PM scores)
時間枠:16 Weeks

The Nasal Symptom Scale is graded on a scale of 0 (no symptom) to 3 (Severe symptom)

16 Weeks
Change in diary symptom scores for the symptoms of facial pain or pressure, measured as instantaneous and reflective scores for the morning and the afternoon (AM and PM scores)
時間枠:16 Weeks

The Nasal Symptom Scale is graded on a scale of 0 (no symptom) to 3 (Severe symptom)

16 Weeks
Change in diary symptom scores for the sense of smell, measured as instantaneous and reflective scores for the morning and the afternoon (AM and PM scores)
時間枠:16 Weeks

Sense of smell will be scored on a scale from 0 (normal) to 3 (absent, no sense of smell)

16 Weeks
The proportions of subjects who have reductions in the AM and PM, instantaneous and reflective, average nasal congestion/obstruction symptom scores by 0.5 or more points from baseline to the end of the double-blind treatment phase
時間枠:16 Weeks

The Nasal Symptom Scale is graded on a scale of 0 (no symptom) to 3 (Severe symptom)

16 Weeks
Subjects will assess their global impression of change since starting the study drug using the PGIC scale
時間枠:16 Weeks

Subject global impression of change will be assessed using a subject-completed PGIC scale, with a single question rated from 1=very much improved to 7=very much worse

16 Weeks
Subjects will assess their change in quality of life since starting the study drug using the quality of life questionnaire (SN-5).
時間枠:16 Weeks

Quality of life assessment using the SN-5 Questionnaire, a subject/parent-completed questionnaire that consists of 5 specific symptoms-related questions (answered on a 7-point Likert scale on the frequency of symptoms, 1=none of the time, 7=all of the time), and 1 general overall quality of life question (answered on a visual analog scale from 0 to 10, worst to best).

16 Weeks
Proportion of subjects eligible for surgical intervention (independent of actual surgery performed)
時間枠:Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination)

The assessment criteria are as follows:

  • Subject has had moderate symptoms of congestion from nasal polyposis for at least 3 months.
  • Subject continues to suffer from at least moderate symptoms despite use of topical steroids at conventional doses for at least 6 weeks.
  • Subject continues to suffer from at least moderate symptoms despite use (or previous use) of saline lavage for at least 6 weeks.
  • Subject has endoscopically visualized bilateral nasal polyposis of at least moderate severity (nasal polyp grading score > 2 in at least 1 nostril). Also assess each subject's eligibility for surgery based on specific of criteria (see Section 12) independent of whether the subject actually undergoes surgery.
Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination)

その他の成果指標

結果測定
メジャーの説明
時間枠
併用薬使用情報収集による安全性評価
時間枠:16週間
16週間
Assessment of safety from physical examination-measuring weight
時間枠:Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination)

Assessment of safety from physical examination-weight measured in kg or lb

Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination)
Assessment of safety from physical examination-measuring height
時間枠:Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination)

Assessment of safety from physical examination-height measured in cm or in

Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination)
Assessment of safety by recording the severity of AEs
時間枠:16 Weeks

Assessment of safety by measuring severity of AEs using scale with 1=mild, 2=moderate, 3=severe

16 Weeks
Assessment of safety by nasal examination
時間枠:16 Weeks

Assessed in nasal examination worksheet which includes recording the presence of any epistaxis, septal erosion/perforation, ulceration/erosion of area other than septum. If present, the nostril location is also recorded, along with severity, and if there is any relation to an injury or trauma

16 Weeks
Assessment of safety by ocular examination-visual acuity
時間枠:Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination)

Assessment of safety by performing visual acuity test assessment using eye chart. Separate recording for each eye in the form of a fraction, 20/...

Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination)
Assessment of safety by ocular examination-Intraocular Pressure
時間枠:Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination)

Assessment of safety by averaging intraocular pressure measurement of 2 or 3 measurements to determine if it is >21mmHg

Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination)
Assessment of safety by ocular examination-Cataract Evaluation
時間枠:Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination)

Cataracts should be again assessed present or absent, If cataract is diagnosed, cataract type per localization should be specified and cataract should be graded 1=mild, 2=moderate, 3=pronounced, 4=severe

Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination)
Assessment of safety measuring vital signs (blood pressure)
時間枠:16 Weeks

Includes systolic and diastolic blood pressure measurements in millimeter of mercury (mmHg)

16 Weeks
Assessment of safety measuring vital signs (pulse)
時間枠:16 Weeks

measure pulse in beats per minute (bpm)

16 Weeks
Assessment of pharmacokinetics - AUC(0-t) (pg*hr/mL)
時間枠:8 hours, 1 to 2 weeks before randomization

PK Laboratory to determine the concentrations of fluticasone propionate [AUC(0-t) (pg*hr/mL) measurement] in human plasma using high performance liquid chromatography (HPLC) with mass spectrometric detection. Approximately 5 mL of blood is collected from each subject at 10 different timepoints over an 8-hour period, for a total of 50 mL. The timepoints are: Pre-dose; 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 3 hours, 6 hours and 8 hours post-dose.

8 hours, 1 to 2 weeks before randomization
Assessment of pharmacokinetics - AUC(0-∞) (pg*hr/mL)
時間枠:8 hours, 1 to 2 weeks before randomization

PK Laboratory to determine the concentrations of fluticasone propionate [AUC(0-∞) (pg*hr/mL) measurement] in human plasma using high performance liquid chromatography (HPLC) with mass spectrometric detection. Approximately 5 mL of blood is collected from each subject at 10 different timepoints over an 8-hour period, for a total of 50 mL. The timepoints are: Pre-dose; 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 3 hours, 6 hours and 8 hours post-dose.

8 hours, 1 to 2 weeks before randomization
Assessment of pharmacokinetics - AUCex (%)
時間枠:8 hours, 1 to 2 weeks before randomization

PK Laboratory to determine the concentrations of fluticasone propionate [AUCex (%) measurement] in human plasma using high performance liquid chromatography (HPLC) with mass spectrometric detection. Approximately 5 mL of blood is collected from each subject at 10 different timepoints over an 8-hour period, for a total of 50 mL. The timepoints are: Pre-dose; 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 3 hours, 6 hours and 8 hours post-dose.

8 hours, 1 to 2 weeks before randomization
Assessment of pharmacokinetics - Cmax (pg/mL)
時間枠:8 hours, 1 to 2 weeks before randomization

PK Laboratory to determine the concentrations of fluticasone propionate [Cmax (pg/mL) measurement] in human plasma using high performance liquid chromatography (HPLC) with mass spectrometric detection. Approximately 5 mL of blood is collected from each subject at 10 different timepoints over an 8-hour period, for a total of 50 mL. The timepoints are: Pre-dose; 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 3 hours, 6 hours and 8 hours post-dose.

8 hours, 1 to 2 weeks before randomization
Assessment of pharmacokinetics - tmax (h)
時間枠:8 hours, 1 to 2 weeks before randomization

PK Laboratory to determine the concentrations of fluticasone propionate [tmax (h) measurement] in human plasma using high performance liquid chromatography (HPLC) with mass spectrometric detection. Approximately 5 mL of blood is collected from each subject at 10 different timepoints over an 8-hour period, for a total of 50 mL. The timepoints are: Pre-dose; 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 3 hours, 6 hours and 8 hours post-dose.

8 hours, 1 to 2 weeks before randomization
Assessment of pharmacokinetics - t1/2 (h)
時間枠:8 hours, 1 to 2 weeks before randomization

PK Laboratory to determine the concentrations of fluticasone propionate [t1/2 (h) measurement] in human plasma using high performance liquid chromatography (HPLC) with mass spectrometric detection. Approximately 5 mL of blood is collected from each subject at 10 different timepoints over an 8-hour period, for a total of 50 mL. The timepoints are: Pre-dose; 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 3 hours, 6 hours and 8 hours post-dose.

8 hours, 1 to 2 weeks before randomization

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディチェア:Amy Manley、Paratek Pharma

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2018年12月31日

一次修了 (実際)

2026年3月31日

研究の完了 (実際)

2026年6月11日

試験登録日

最初に提出

2018年10月23日

QC基準を満たした最初の提出物

2018年11月16日

最初の投稿 (実際)

2018年11月20日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月18日

QC基準を満たした最後の更新が送信されました

2026年9月15日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • OPN-FLU-NP-3103

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する